Marcus B. Silva

Chief Marketing Officer
Mr. Silva has over 17 years of sales, marketing and general management experience in healthcare delivery, medical devices and diagnostics, and pharmaceuticals. Mr. Silva joined NeoGenomics in June 2020 as the Chief Marketing Officer, after leading Precision Medicine efforts at Novartis resulting in the the successful 2019 launch of PIQRAY (alpelisib) and 2020 launch of TABRECTA (capmatinib).
Prior to Novartis, Mr. Silva was with Becton Dickinson (BD) where he first led global strategic marketing excellence for their $1B global injection business and later was appointed head of Marketing and Analytics for their $700M US Diabetes Care business. Prior to BD, Mr. Silva was with Johnson & Johnson’s Ortho-Clinical Diagnostics franchise, where he held various leadership roles within Global Marketing, Strategic Marketing and Regional Marketing, including multiple product and campaign launches. Prior to this, Mr. Silva started his own healthcare company based in Southern California that focused on senior care, which he ran for almost 10 years and grew to over 100 employees. Additionally, Mr. Silva began his career as a practicing California plaintiff’s attorney, litigating employment law cases in Southern California.
Mr. Silva earned his BA from Rutgers University, his JD from California Western School of Law, and his MBA from Rutgers Business School, with a focus on Marketing and Pharmaceutical Management.